Merck & Co., Inc. and Ligand Pharmaceuticals Incorporated: A Detailed Gross Profit Analysis

Merck vs. Ligand: A Decade of Gross Profit Trends

__timestampLigand Pharmaceuticals IncorporatedMerck & Co., Inc.
Wednesday, January 1, 20145540200025469000000
Thursday, January 1, 20156610700024564000000
Friday, January 1, 201610340200025916000000
Sunday, January 1, 201713573600027347000000
Monday, January 1, 201824511600028785000000
Tuesday, January 1, 201910893500032728000000
Wednesday, January 1, 202015600000027900000000
Friday, January 1, 202121495700035078000000
Saturday, January 1, 202214341800041872000000
Sunday, January 1, 20239626500043989000000
Loading chart...

In pursuit of knowledge

A Tale of Two Giants: Merck & Co., Inc. vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market prowess. This analysis delves into the gross profit trends of Merck & Co., Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this decade, Merck has consistently outperformed Ligand, with its gross profit peaking at approximately $44 billion in 2023, marking a 73% increase from 2014. In contrast, Ligand's gross profit saw a more modest growth, peaking at around $245 million in 2018, before experiencing fluctuations.

Key Insights

  • Merck's Dominance: Merck's gross profit in 2023 is nearly 180 times that of Ligand's, highlighting its dominant market position.
  • Ligand's Volatility: Ligand's profits have been more volatile, with significant peaks and troughs, reflecting its dynamic business model.

This comparative analysis underscores the diverse strategies and market positions of these two pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025